Shionogi Deal Opens Asia To Sage’s Fast-Acting Antidepressant
Executive Summary
Japan’s Shionogi has gained selected Asian rights to Sage’s promising fast-acting depression drug, in a deal worth up to $575m to the US company.
You may also be interested in...
Sage's Regulatory Strategy For Zuranolone Remains Uncertain
The company said it will update investors on the path forward for zuranolone in major depressive disorder after finalizing discussions with the US FDA. It would not confirm if a meeting had taken place yet.
Sage Impresses With Second Postpartum Depression Therapy
Positive top-line Phase III data with Sage's second lead positive allosteric modulator at GABA receptors, SAGE-217, in postpartum depression continues to back the US biotech's approach to the devastating condition.
Deal Watch, Focus On Asia: Cipla Licenses India Rights To Lilly’s Basalgar
Cipla expands on its in-licensing strategy in India with Lilly’s insulin glargine product, while Aptose signs second agreement with CrystalGenomics to add Chinese rights for leukemia candidate CG-806, and Yakult gains Japanese rights to Verastem's duvelisib.